Price close 16 Nov 2026
- 1M
- −1.1%
- 6M
- +13.4%
- YTD
- +21.5%
- 1Y
- +30.0%
- 3Y
- +108%
- 10Y
- +125%
Price change over each period, from daily closes; dividends not included.
Price change over each period, from daily closes; dividends not included.
State Street SPDR S&P Biotech ETF (XBI) is a health care sector equity exchange-traded fund from State Street, tracking the S&P Biotechnology Select Industry Index.
It charges 0.35% a year — $35.00 on $10,000, and holds 167 positions, the ten largest 18.4% of the fund.
Its net assets were $10.4 billion on November 12, 2026; it is the 4th largest of the 4 health care funds among the 300 largest ETFs.
From the fund's prospectus and its latest holdings (12 Nov 2026), compiled and checked by AapWire.
| Holding | Weight | Weight bar |
|---|---|---|
| Moderna Inc MRNA | 2.55% | |
| Exelixis Inc EXEL | 1.79% | |
| Amgen Inc AMGN | 1.78% | |
| Biogen Inc BIIB | 1.78% | |
| Spyre Therapeutics Inc SYRE | 1.77% | |
| Tg Therapeutics Inc TGTX | 1.77% | |
| Regeneron Pharmaceuticals REGN | 1.76% | |
| Abbvie Inc ABBV | 1.75% | |
| United Therapeutics Corp UTHR | 1.75% | |
| Gilead Sciences Inc GILD | 1.73% |
| Health Care | 99.5% |
|---|---|
| Financials | 0.5% |
The eleven sectors of the company pages: an S&P 500 member counts in its index sector, any other holding in its industry's; shares of the stock that has a sector.
Countries as the fund reports them: US 92.9%, CA 0.1%.
Money put into the fund less money taken out, from the change in its shares outstanding at each day's net asset value; the record starts 10 Sep 2021.
| Category | Health care · Sector equity |
|---|---|
| Issuer | State Street |
| Index | S&P Biotechnology Select Industry Index |
| Expense ratio | 0.35% · $35.00 a year on $10,000 |
| Net assets | $10.4B · 12 Nov 2026 |
| Holdings | 167 · ten largest 18.4% |
| Legal form | Registered fund |
| Rank in category | 4 of 4 · by size, among the 300 largest ETFs |
| Year | Total return |
|---|---|
| 2024 | 1.1% |
| 2023 | 7.5% |
| 2022 | -25.8% |
| 2021 | -20.5% |
| 2020 | 48.2% |
| 2019 | 32.2% |
| 2018 | -14.9% |
| 2017 | 43.7% |
| 2016 | -15.4% |
| 2015 | 13.6% |
From the prospectus filed 24 Oct 2025.
XBI's expense ratio is 0.35% a year, $35.00 on a $10,000 holding, from its latest prospectus.
XBI tracks the S&P Biotechnology Select Industry Index.
XBI held 167 positions on November 12, 2026.
Moderna Inc (2.6%), Exelixis Inc (1.8%), Amgen Inc (1.8%), Biogen Inc (1.8%), Spyre Therapeutics Inc (1.8%).
XBI is issued by State Street; it is a registered fund.
In the terminal
The fund's costs and returns are read from its prospectus, its positions from its latest report or its issuer's own file, and its category from what it holds and how it names itself. A figure that cannot be read is left blank. See data and methodology.